Want to see GOSS full AI Analyst Report?
GOSS Stock Chart & Stats
$0.14
>-$0.01(-4.56%)
At close: 4:00 PM EDT
$0.14
>-$0.01(-4.56%)
Day’s Range― - ―
52-Week Range$0.11 - $3.87
Previous CloseN/A
Volume10.93M
Average Volume (3M)17.32M
Market Cap
$87.16M
Enterprise Value$180.63
Total Cash (Recent Filing)$99.22M
Total Debt (Recent Filing)$202.93M
Price to Earnings (P/E)―
Beta1.52
Next Earnings
Aug 11, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.79
Shares Outstanding488,846,700
10 Day Avg. Volume21,877,037
30 Day Avg. Volume17,317,995
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)-5.77
Price to Sales (P/S)14.62
P/FCF Ratio-4.13
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$1.07Price Target Upside664.29% Upside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)-0.37
Revenue Forecast (FY)$34.64M
Bulls Say, Bears Say
Bulls Say
Regained Seralutinib Rights & NDA ControlReacquiring worldwide rights consolidates development, manufacturing and pricing control, allowing Gossamer to capture greater economic upside from seralutinib. This structural change aligns incentives for a focused NDA push and long-term commercialization planning, reducing partner dependency.
Mechanistic Imaging Evidence (CT FRI)Robust CT FRI mechanistic data that correlates structural changes with clinical outcomes strengthens biological plausibility and the evidentiary package. Such durable mechanistic support can materially de‑risk regulatory review and payer/physician acceptance over a multi‑year commercialization horizon.
Convertible Debt RestructuringReducing near‑term convertible obligations and extending maturities materially lowers immediate refinancing pressure and provides multi‑year breathing room. A successful restructure improves financial flexibility for NDA execution and commercialization, though it reshapes dilution and coupon obligations.
Bears Say
Short Cash RunwayA runway to only Q1 2027 forces dependence on near‑term financing outcomes or successful NDA acceptance. This creates persistent execution risk: additional dilution, rushed commercial preparations, or disruptive cost cuts could be required, impairing long‑term program and go‑to‑market plans.
Negative Equity & Balance Sheet ContractionNegative equity reflects cumulative losses and a weakened capital base, reducing borrowing capacity and negotiating leverage with partners. A materially contracted balance sheet limits strategic optionality, increases refinancing dependency, and raises structural solvency concerns over the medium term.
Primary Endpoint Statistical ShortfallMissing the prespecified alpha introduces regulatory uncertainty that can prolong review, require additional analyses or confirmatory work, and weaken label claims. This structural approval risk affects timeline, required evidence package and potential commercial positioning independent of secondary signal strength.
Gossamer Bio News
GOSS FAQ
What was Gossamer Bio’s price range in the past 12 months?
Gossamer Bio lowest stock price was $0.11 and its highest was $3.87 in the past 12 months.
What is Gossamer Bio’s market cap?
Gossamer Bio’s market cap is $87.16M.
When is Gossamer Bio’s upcoming earnings report date?
Gossamer Bio’s upcoming earnings report date is Aug 11, 2026 which is in 10 days.
How were Gossamer Bio’s earnings last quarter?
Gossamer Bio released its earnings results on May 18, 2026. The company reported -$0.2 earnings per share for the quarter, missing the consensus estimate of -$0.166 by -$0.034.
Is Gossamer Bio overvalued?
According to Wall Street analysts Gossamer Bio’s price is currently Undervalued.
Does Gossamer Bio pay dividends?
Gossamer Bio does not currently pay dividends.
What is Gossamer Bio’s EPS estimate?
Gossamer Bio’s EPS estimate is -0.12.
How many shares outstanding does Gossamer Bio have?
Gossamer Bio has 488,846,700 shares outstanding.
What happened to Gossamer Bio’s price movement after its last earnings report?
Gossamer Bio reported an EPS of -$0.2 in its last earnings report, missing expectations of -$0.166. Following the earnings report the stock price went down -43.529%.
Which hedge fund is a major shareholder of Gossamer Bio?
Currently, no hedge funds are holding shares in GOSS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Gossamer Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$1.07 (664.29% Upside)
$1.07 (664.29% Upside)
Blogger Sentiment
Bullish
GOSS Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 3.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 1.0%
Last 30 Days ▼ 1.9%
Last 30 Days ▼ 1.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-92.35%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-54.06%
Trailing 12-Months
Company Description
Gossamer Bio
Gossamer Bio, Inc. (GOSS) is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing medicines for patients with immunologic and inflammatory diseases and, historically, select oncology programs. The company’s activities center on advancing a pipeline of drug candidates through clinical development, with a strategic focus on immunology and inflammation assets.
GOSS Company Deck
GOSS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed but constructive picture: clinically meaningful efficacy signals (including a traditional statistical threshold for 6MWD), supportive mechanistic CT FRI data across multiple lung compartments with clinical correlations, and decisive capital actions (debt reduction plan and cost containment) to preserve runway and focus on an NDA path. Counterbalancing these positives were key execution risks — the primary endpoint did not meet the prespecified alpha, a substantial workforce reduction was implemented, cash runway is short ($99M to Q1 2027), and the debt exchange depends on high noteholder participation and involves tradeoffs. Overall, the tone is cautious and pragmatic, emphasizing strengthened conviction in the program but acknowledging material near-term financial and regulatory risks.View all GOSS earnings summariesGOSS Stock 12 Month Forecast
Average Price Target
$1.07
▲(664.29% Upside)
Technical Analysis
Aldeyra Therapeutics
―
Cue Biopharma
―
Tiziana Life Sciences
―
Alector
―
Connect Biopharma Holdings
―
Ownership Overview
1.86% Insiders
3.62% Mutual Funds
6.68% Other Institutional Investors
83.83% Public Companies and
Individual Investors